Floatz logo

.ALPHA.-1 PROTEASE INHIBITOR

Cystic Fibrosis

Kamada, Ltd.protein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
73/ 100

Competitive context

82 Active assets in the Cystic Fibrosis cohort.

Asset / SponsorPhaseRating
Tezacaftor
Vertex Pharmaceuticals Incorporated
Phase 4A
Lumacaftor
Hospices Civils de Lyon
Phase 4BBB
Liprotamase
Anthera Pharmaceuticals
Phase 4BBB
Ivacaftor
Meyer Children's Hospital IRCCS
Phase 4BBB
ELEXACAFTOR
Meyer Children's Hospital IRCCS
Phase 4BBB

View all 50 →

Same molecule, other indications

.ALPHA.-1 PROTEASE INHIBITOR is also rated in:

alpha 1-antitrypsin deficiencyDormant
A
Indicative ·
81 / 100
View asset →
Chronic Obstructive Pulmonary DiseaseDormant
BBB
Indicative ·
72 / 100
View asset →
alpha 1-antitrypsin deficiencyDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →